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studied include age (<45 vs. ≥45 years), hypertension, diabetes, congestive heart 
failure (CHF, history of heart failure or ejection fraction [EF] ≤40%), gender,  
prior MI, final diagnosis, and MI type. RESULTS: Of 1166 consecutive patients, 
1073 underwent CAG, considered eligible: normal coronaries, 113 (10.5%); leaving 
960 patients with CAD (MI [289, 30.1%], UA [604, 62.9%], Undetermined ACS [32, 
3.3%], CSA [35, 3.7%]); 30% patients were diabetic. Proportion of hypertensive 
patients was significantly higher among diabetics (57.7% vs. 34.9% non-diabetics, 
P<0.001). The presence of CHF in the diabetic as well as non-diabetic patients 
was similar. For all patients with CAD, around 40% had SVD on CAG; for 
diabetics, 35% patients had TVD whereas the proportion was only 24% among 
non-diabetics. In the linear stepwise regression, age ≥45 years, presence of CHF 
and diabetes showed significant positive correlation with the severity of CAD 
(p<0.05). CONCLUSIONS: Clustering of several cardiovascular risk factors at 
presentation may lead to the worse prognosis in patients with CAD from India. 
Findings from this study ascertain more severe angiographic findings in diabetic 
patients than that in non-diabetic controls regarding the severity of CAD.  
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OBJECTIVES: To explore the association between race, comorbidities, and 
therapy use among patients with heart failure (HF) in a contemporary Medicaid 
population. METHODS: Medical/prescription/enrollment records from the 
Maryland State Medicaid Managed Care Organization/Fee-for-services, ages 18-
64, non-dual enrolled, with HF diagnosis between July 1, 2005 to December 31, 
2009, followed at least 3 months. Diagnosis for HF defined as earliest encounter 
claim that included ICD-9 code 428.xx. Comorbidity diagnosis determined 
between earliest claim and within three months post-HF diagnosis. First-line 
therapies ascertained using pharmacy claims with first-date-of-service between 
HF diagnosis and the end of follow up. Variation in comorbidities and therapy 
use across race/ethnicity is described. RESULTS: Among 15,764 HF patients, 60% 
(n=9,388) were black, 33% (n=5,158) white, 6% (n=919) other, 2% (n=299) Hispanic. 
Over half were female (55%); 72% older than 44 years. Prevalence in 
race/ethnicity: COPD (40% white, 22% black, 20% other, 11% Hispanic; p<0.001), 
stroke (20-22%; p=0.17), renal dysfunction (38% Hispanic, 30% black, 27%other, 
22% white; p<0.001), diabetes (38-42%; p=0.04), psychological disorder (65% white, 
52% black, 46% other, 37% Hispanic; p<0.001), hyperlipidemia (44% white, 39% 
Hispanic, 31% other, 33% black; p<0.001), chronic ischemic heart disease (47% 
white, 41% black/Hispanic/other; p<0.001), hypertension (76% black, 72% 
Hispanic, 68% white, 67% other; p<0.001), other cardiovascular disease (76-80%; 
p=0.17). Excluding other cardiovascular disease, the median number of comorbid 
conditions was 3 in each race/ethnicity. Among black, white, Hispanic and other, 
only 5.8%, 4.4%, 9.0%, and 7.3% had zero comorbidities, and 14.2%, 11.4%, 12.4%, 
15.8% had only one comorbidity, respectively. Hispanics (53%) were less likely 
than blacks (62%), whites (61%), or others (57%) to be prescribed ACE-
inhibitor/ARB, beta-blockers, aldosterone antagonists, and/or other 
cardiovascular drugs including combination nitrates/hydralazine (p<0.001). 
CONCLUSIONS: Whites were most likely to be diagnosed with COPD, 
psychological disorders, hyperlipidemia, and chronic ischemic heart disease. 
Hypertension was most likely among Blacks, and renal dysfunction most likely 
among Hispanics.  
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OBJECTIVES: Increasing prevalence of heart failure, increasing enrollment in 
state programs, sparse literature on population-based heart failure studies, and 
the associations between lower socioeconomic status and increased comorbidity 
burden necessitate an examination of the prevalence of HF comorbidities in a 
contemporary Medicaid population. METHODS: Medical/prescription/enrollment 
records from the Maryland State Medicaid Managed Care Organization/Fee-for-
services, ages 18-64, non-dual enrolled, with HF diagnosis between July 1, 2005 to 
December 31, 2009, followed at least 3 months. Diagnosis for HF defined as 
earliest encounter claim that included ICD-9 code 428.xx. Comorbidity diagnoses 
determined between earliest claim and within three months post-HF diagnosis. 
The frequencies and cross-frequencies of the selected comorbidities are 
examined. RESULTS: Among 15,764 HF patients, 60% (n=9,388) were black, 33% 
(n=5,158) white, 6% (n=919) other, 2% (n=299) Hispanic. Over half were female 
(55%); 29% were ages 18-44, 36% ages 45-54, and 36% ages 55-64. The most 
common comorbidity was other cardiovascular disease (CVD, 78%), followed by 
hypertension (73%), psychological disorder (57%), chronic ischemic heart disease 
(43%), diabetes (41%), hyperlipidemia (37%), chronic obstructive pulmonary 
disease (28%), renal dysfunction (28%), and stroke (21%). This pattern persisted 
within any particular comorbidity group. Excluding hypertension and other CVD: 
10% of patients had zero comorbidities, 20% had only one, 70% had multiple 
comorbidities; 0.7% (n=114) had every comorbidity above. The median number of 
comorbidities was 2; median being 4 if hypertension and other CVD are included. 
CONCLUSIONS: An overwhelming majority of HF patients enrolled in Maryland 
Medicaid have multiple comorbidities. The prevalence of any comorbidity above 
was no less than 21%; the most prevalent comorbidities being hypertension, 
other CVD, and psychological disorder. Our findings call attention to the level 
comorbidity in a high-risk Medicaid population, reflecting a demographic largely 
under-represented in large scale studies or clinical trials. Future research should 
identify clinical and hospitalization issues associated with prevalent disease in 
this population.  
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OBJECTIVES: Increasing prevalence of heart failure (HF), increasing enrollment in 
state programs, sparse literatures on population-based heart failure studies, and 
the burden of hospitalization among Medicaid patients necessitate an analysis of 
risk factors for heart failure hospitalization in a contemporary Medicaid population. 
METHODS: Claims from Maryland State Medicaid, for 14,149 non-dually enrolled, 
18-64 year olds with a diagnosis for HF between 7/1/05-12/31/09, followed for at 
least six months. We examine the effects of comorbidity and first-line therapy use 
on the risk of any hospitalization after HF diagnosis. Multivariate Weighted Cox 
Regressions were used to address non-proportional risk of hospitalization over the 
follow-up period. We report numbers needed to treat with first-line therapy to 
prevent one hospitalization annually. RESULTS: Most patients were >45 years (71%), 
female (56%), and black (60%). Use prevalence was: beta-blockers (26%), ACE-
inhibitors/ARB (29%), aldosterone antagonists (AA, 5%), and others including 
nitrates+hydralazine (37%). Nearly all (98%) were diagnosed with one or more 
comorbidities. Relative risk (95% CI) for any hospitalization was 1.43 (1.36-1.51) renal 
dysfunction, 1.40 (1.31-1.50) other cardiovascular, 1.33 (1.26-1.40) COPD, 1.28 (1.22-
1.35) chronic ischemic heart disease, 1.27 (1.20-1.34) stroke, 1.26 (1.20-1.32) diabetes, 
1.11 (1.05-1.17) hypertension, 0.81 (0.77-0.85) hyperlipidemia, 0.77 (0.73-0.81) 
psychological disorder; 0.77 (0.73-0.81) ACE inhibitor/ARB, 0.83 (0.79-0.87) beta-
blocker, 0.76 (0.72-0.80) other cardiovascular drugs. AA and/or nitrates+hydralazine 
combination had no impact. The C-statistic for predicted 1-year hospitalization risk 
within the sample was 0.80. Numbers needed to treat to prevent one hospitalization 
annually: 12 ACE-inhibitor/ARB, 15 beta-blockers, or 11 other cardiovascular drugs. 
CONCLUSIONS: We elicit the specific risk attributable to lead risk factors in HF 
patients enrolled in Medicaid plans, and show certain disease modifying therapies 
can quantifiably mitigate risk of hospitalization. Growing ranks of state Medicaid 
plans and other entitlement programs call for more deliberate, proactive and cost-
effective disease and risk management of plan enrollees.  
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OBJECTIVES: Venous thromboembolism (VTE) includes deep-vein thrombosis 
(DVT) and pulmonary embolism (PE), with a considerable risk of recurrence and 
mortality. This study examined the recurrence rate and associated risk factors in 
hospitalized patients with acute VTE in the US clinical practice setting. 
METHODS: Adult patients with VTE were selected from the linked MarketScan 
and Hospital Discharge database in an inpatient setting between 07/01/2006-
12/31/2011. The first hospitalization with a diagnosis of VTE (ICD-9-CM: 451-453, 
671.3, 671.4, 671.9, 415.1, 673.2, or 673.8) was designated as index hospitalization. 
Patients were required to have at least 6 months continuous enrollment and 
have no VTE diagnosis in the 6 months prior to index hospitalization. Patients 
were followed until the earliest of VTE recurrence, death, disenrollment, or the 
end of study. VTE recurrence was defined as re-hospitalization with VTE at least 
1 day after discharge from index hospitalization. Cox regression was used to 
model time to recurrence and examine demographic and clinical factors 
associated with recurrence. RESULTS: A total of 957 patients were eligible for the 
study, including 570 patients with DVT only (59.6%); 237 with PE only (24.7%); and 
150 with both DVT and PE (15.7%). Mean age was 62.8 years (SD=15.2), and 432 
were male (45.1%). Mean follow-up time was 23.1 months. During follow-up, 146 
patients recurred, with a recurrence rate of 15.3%. The average time to 
recurrence was 20.1 months (median=15.4). Number of comorbid conditions as 
measured by Charlson Comorbidity Index was independently associated with 
increased risk for VTE recurrence (hazard ratio [HR]: 1.12, 95%CI=1.05 – 1.20). 
CONCLUSIONS: More than 15% of hospitalized patients with acute VTE recurred 
during an average follow-up period of 23 months in the real clinical setting. 
Comorbidities were associated with increased risk for recurrence. Further 
research needs to examine recurrence and its economic outcomes associated 
with VTE treatment patterns.  
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OBJECTIVES: High-dose statin therapy has been reported to be associated with 
increased risk of side effects, which may reduce treatment adherence and 
impact cardiovascular (CV) outcomes. This study assessed association between 
initial statin dose and treatment adherence and persistence and its impact on CV 
outcomes in the overall and sub-population with prior CV events. METHODS: An 
observational, retrospective study was conducted in a UK linked database (CPRD) 
comprising primary care, secondary care (Hospital Episode Statistics), and 
